Skip to main content

Oncology Practice Landscape in 2018: ASCO Survey Shows Interactions with Payers Top Concern

Web Exclusives - Practice Management
Eileen Koutnik-Fotopoulos

Oncology practices are challenged by day-to-day operational functions, which are often related to payment, reimbursement, and competition, according to the new survey titled “The State of Oncology Practice in America” from the American Society of Clinical Oncology (ASCO) on the oncology practice landscape in the United States.

“The State of Oncology Practice in America” was published in the Journal of Oncology Practice in July 2018,1 and is part of the ASCO State of Cancer Care in America series.

The survey highlights key trends in oncology practice management and practice concerns, as well as information on the size, geographic distribution, use of electronic health records (EHRs), and number of oncology practices.

“Time spent by providers dealing with EHRs, prior authorizations, and other reporting requirements competes with resources to deliver high-quality patient care,” stated M. Kelsey Kirkwood, MPH, Research and Analyst Specialist at ASCO, and colleagues.

Response Rate and Type of Practices

For this survey, ASCO used Medicare Physician Compare data to identify oncology practices in the United States. The survey examined trends in the number and sizes of practices from 2013 to 2017.

More than 2200 hematology/oncology practices provided care to adults in 2017. Of those practices, 394 (18%) completed the survey and accounted for 58% of the hematologist/medical oncologist US workforce (N = 7203).

The majority of the practices were physician owned (42%), followed by hospital health system owned (37%) and academic (21%); the distribution was nearly identical to that of the 2016 census cohort. The following are the key findings of the report.

Key Concerns for Oncology Practices

  1. Interactions with payers was cited as a key challenge in 2017 by the majority of practices.

    Overall, 58% of responding oncology practices reported payer pressures as the top concern. This was a significant increase over concerns reported in 2016, when payer pressures ranked as the fourth concern. Among these practices, prior authorizations (75%) and coverage denials and appeals (62%) were the biggest payer stressors that they face.

    Other top concerns included competitive pressures, staffing issues, and increasing expenses.

  2. EHRs remained a burden on practices, with only 15% reporting full interoperability.

    Of the responding practices, 57% could use their EHR to send data to a clinical registry, and 60% could send electronic copies of EHR data to patients.

    “With much energy spent at the practice and provider levels, it is unfortunate to find within our Census cohort that EHRs are still largely unable to transfer data seamlessly and consistently to one another, let alone to patients and to cancer registries,” noted Ms Kirkwood and colleagues.1

  3. The majority of practices are prepared to comply with the Medicare Merit-Based Incentive Payment System (MIPS).

    Of the responding practices, 58% reported that they were ready to comply with MIPS; preparedness was especially high (74%) among physician-owned practices. However, more than 33% of practices are still unsure if they are ready, leaving 8% of practices unprepared for the 2019 deadline.

  4. Consolidation continues, but more than 50% of practices remain small.

    As of 2017, there were 2248 oncology practices in the United States and 12,423 US-based hematologists, hematologists/oncologists, and medical oncologists.

    From an extraction of 2016 Physician Compare data, the researchers identified 2427 oncology practices, representing a 2.6% decrease in the number of oncology practices from 2016 to 2017. Annual declines in the number of practices were observed dating back to 2013 (range, 0.3%-5.1%).

    Despite this consolidation, 76% of practices employ 1 to 5 oncologists, and 72% report only 1 site. Of the practices, 21% employ 6 to 40 oncologists and 3% employ ≥41 oncologists. In total, 25% of practices have 2 to 5 sites and 3% have 5 to 10 sites.

  5. The oncology practice landscape continues to evolve.

    Many of the practices reported changes in organization structure, with 34% citing closures, openings, mergers, and/or sales, which represents a more than 2-fold increase compared with 16% in 2016.

    Of the practices that reported changes in 2017, 53% opened new sites, 27% merged with others, 25% purchased other sites, 21% closed sites, and 6% sold sites.

  6. Access to cancer care is low in rural areas, high in the South.

    A total of 19% of the US population resides in rural areas; however, only 7% of oncologists practice in rural areas. The South had the largest (33%) share of practices and the highest cancer burden, with 38% of new cancer cases diagnosed in 2017.

Practical Implications

The researchers noted that these “findings likely represent conservative estimates of such burdens because they are driven by responses from midsized to large-sized organizations, which tend to have lower relative administrative burden and greater market influence than small practices and therefore may be able to adapt more readily to changes in the health care environment.”1

ASCO intends to increase its outreach among small practices in the future to better capture their practice experiences.


  1. Kirkwood MK, Hanley A, Bruinooge SS, et al. The state of oncology practice in America, 2018: results of the ASCO Practice Census survey. J Oncol Pract. 2018;14:e412-e420.
Related Items
Artificial Intelligence and the Future of Healthcare
Fop Johnson
Web Exclusives in Practice Management
Artificial intelligence tools and applications have shown great promise in delivering higher quality healthcare, but current offerings are at various stages of maturity and capability and are not yet in widespread use.
CMOM-HEM/ONC Course: A Valuable Resource for Practice Managers
Ina Huang
Web Exclusives in Practice Management
In the evolving landscape of today’s healthcare industry, more and more demands are being placed on practice managers and their staff.
The Flaw in Infusion Scheduling
Web Exclusives in Practice Management
In reality, scheduling appointments with significant lead times, often weeks or months before the actual appointment, may actually cause more problems and serve fewer patients.
Applying Business Principles to Everyday Practice
Meg Barbor, MPH
Web Exclusives in Practice Management
Given the high cost of oncology drugs, it is important for pharmacists to become more business savvy regarding their practices.
Identifying the Problem Is Key to Quality Improvement in Cancer Care
Meg Barbor, MPH
Web Exclusives in Practice Management
“There are a number of ways to go wrong when you’re trying to improve something,” said Kaveh G. Shojania, MD, Director, Centre for Quality Improvement and Patient Safety, University of Toronto, Canada, and Editor-in-Chief, BMJ Quality & Safety, who delivered the keynote address at the 2018 ASCO Quality Care Symposium.
FDA Perspective: Reducing Cost, Increasing Access to Cancer Care
Chase Doyle
Web Exclusives in Practice Management
In a time when the country feels more politically divided than ever, there is broad consensus that Medicare should be allowed to negotiate prescription drug prices directly with drug makers, and that the FDA should expedite approvals of generic cancer drugs to lower patients’ out-of-pocket costs.
One Oncologist’s Firsthand Experience with Serious Illness: What Your Patients Want
Meg Barbor, MPH
Web Exclusives in Practice Management
There’s really only one way to identify how patients are coping with serious illness: by asking them, according to Thomas J. Smith, MD, FACP, Director of Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD.
Harnessing the Power of Data Collection and Coordination in Oncology Practice
Meg Barbor, MPH
Web Exclusives in Practice Management
Business intelligence is the process of collecting data from disparate systems—internal and external—and turning it into information that is meaningful and actionable toward achieving strategic goals.
MIPS: How to Be Successful Today and in the Future
Toni Gress
Web Exclusives in Practice Management
The McKesson value-based care team employs a combination of tactics to help practices in The US Oncology Network achieve success in the Merit-Based Incentive Payment System (MIPS). One of the challenges with the new MIPS program is the need to focus on the current year’s performance, while taking steps to ensure that practices are successful in future years.
FDA Commissioner Outlines New Plan to Increase Biosimilars by “Balancing Innovation and Competition”
Eileen Koutnik-Fotopoulos
Web Exclusives in Practice Management
FDA Commissioner Scott Gottlieb, MD, has been outspoken about the critical need to reign in drug prices. Biosimilars are crucial for improving patient access to biologic drugs at an affordable cost. Biologics are now key in the treatment of cancer and autoimmune conditions. But cost remains an obstacle to access to drug therapy.
Last modified: June 11, 2020